摘要
目的:观察支气管哮喘患者呼出气冷凝液(EBC)中半胱氨酰白三烯C4(LTC4)、8异前列腺素(8-isoprostane)、硝酸盐/亚硝酸盐(NO2/NO3)水平及孟鲁司特干预前后炎症指标的变化。方法:选择哮喘非急性发作期患者30例,均予孟鲁司特10mg,每晚一次口服,疗程1月,分别于治疗前及治疗后检测EBC中LTC4、8-isopros-tane、NO2/NO3水平,另选择30例健康人为健康对照组。结果:哮喘组LTC4(55±17)ng/mL、8-isoprostane(13±9)ng/mL、NO2/NO3(4.2±1.2)ng/mL显著高于正常对照组(17±17)、(7±6)、(3.2±0.6)ng/mL(均P<0.01)。哮喘组治疗前LTC4(55±17)ng/mL显著高于治疗后(38±14)ng/mL,P<0.01。哮喘组治疗前8-isoprostane(13±9)ng/mL,高于治疗后(11±6)ng/mL,但差异无统计学意义(P>0.05)。哮喘组治疗前NO2/NO3水平为(4.2±1.2)ng/mL,治疗后为(4.1±1.4)ng/mL,差异无统计学意义(P>0.05)。结论:检测哮喘患者EBC中LTC4、8-isoprostane、NO2/NO3水平可简便安全监测哮喘的气道炎症,孟鲁司特能降低EBC中LTC4水平,是一种有效的气道炎症抑制剂。
AIM： To investigate the levels of leukotrienes C4 （LTC4）, 8-isoprostane, nitrite / nitrate（NOz/NO3） in exhaled breath condensate of patients with asthma and the effect of inflam- matory factors after montelukast treatment. METHODS： 30 patients with asthma were en- rolled. They were given 10 mg montelukast once each night for one month. Before starting thera- py and one month later, the levels of LTC4, 8- isoprostane, NO2/NO3 in exhaled breath con- densate were measured. RESULTS：The levels of LTC4 （55 ± 17） ng/mL, 8-isoprostane （13 ±9） ng/mL, and NO2/NO3 （4.2 ±1.2） ng/mL were significantly higher in the asthma group than those in the control group （17±17） , （7± 6） , （3.2±0.6） ng/mL（P〈0.01）. The levels of LTC4 （55±17） ng/mL in patients with asth- ma before treatment was significantly higer thanthose in patients after treatment （ 38 ±14） ng/mL（P〈0.01）. Before and after treat- ment,the levels of 8-isoprostane,NO2/NO3 were （13 ± 9）, （11 ±6）, （4.2 ±1.2）, （4.1 1.4） ng/mL; and there were no significant differences （ P 〈 0.05）. CONCLUSION ： Detec- ting the LTC4, 8-isoprostane and NO2/NO3 in EBC can be used to monitor asthmatic airway inflammation, which are convenient, noninvasive and safe. Montelukast can decrease the level of LTC4, which is an effective anti-inflammatory agent.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2012年第7期802-805,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
绍兴市科技局基金项目(2009A33028)
